IMMUNISATION: THE GATEWAY TO HEALTH AND ECONOMIC DEVELOPMENT

- Immunisation landscape
- Return on investment
- Affording immunisation
- Cost of inaction
- Taking action

Dr. Seth Berkley,
CEO Gavi, the Vaccine Alliance
April 2016, UNECA meeting
IMMUNISATION:
THE GATEWAY TO
HEALTH & ECONOMIC DEVELOPMENT

Dr. Seth Berkley,
CEO Gavi, the Vaccine Alliance
April 2016, UNECA meeting

www.gavi.org
IMMUNISATION LANDSCAPE

Traditional vaccines:
- Measles
- Tuberculosis
- Poliomyelitis
- Diphtheria
- Tetanus
- Pertussis
- Smallpox

Gavi-supported new vaccines:
- Human papillomavirus
- Pneumococcal disease
- Rotavirus gastroenteritis
- Haemophilus influenzae type b
- Meningococcal Disease
- Rubella
- Hepatitis B
- Yellow fever
- Cholera
- Japanese encephalitis
RETURN ON INVESTMENT

Income growth + Value of life years gained in that period = Change in country's full income over time period

3x Public infrastructure
3x Pre-school education
9x Community health workers
16x Immunisation

44x (full income approach)
16x (cost of illness)

The Economic Benefits of Public Infrastructure Spending in Canada. The Centre for Spatial Economics, September 2015
The rate of return to the HighScope Perry Preschool Program. Department of Economics, University of Chicago, April 2009
BEHIND IMMUNISATION’S ROI

- Immunisation investment
- Reduced sickness
- Improved learning
- Reduced caretaker burden
- Increased productivity
- Healthcare savings
- GNI increase
ONE VACCINE-PREVENTABLE DEATH EVERY TEN SECONDS

WHY?

• People in remote locations
• Inadequate monitoring
• Limited resources
• Competing health priorities
• Political will
WHO RECOMMENDED ANTIGENS

- BCG (1 dose)
- DTP (3 doses)
- Hepatitis B (3 doses)
- Hib (3 doses)
- Pneumococcal (3 doses)
- Polio (OPV, 3 doses)
- Rotavirus (2 or 3 doses)
- Measles (2 doses)
- Rubella (1 dose with Measles)
- HPV (2 doses)
WHO RECOMMENDED ANTIGENS: HPV

Annual causes of death in women

Child birth 289,000

Cervical cancer 266,000

HPV vaccines prevent against cervical cancer 70%

• HPV (2 doses)
VACCINE PORTFOLIO: COST

Approx. USA price $950
THE GAVI MODEL: AFFORDABILITY

Purchasing for 60% of world’s birth cohort

Approx. USA price

Gavi price

$35
THE GAVI MODEL: CO-FINANCING

Co-financing vaccine purchase

Country

Gavi

Gavi price

$35

Purchasing for 60% of world’s birth cohort
SHARING THE INVESTMENT

VACCINES AS % OF GENERAL GOVERNMENT SPENDING

GNI < US $1,000

0.42%  Gavi contribution

0.08%  Country contribution
SHARING THE INVESTMENT

VACCINES AS % OF GENERAL GOVERNMENT SPENDING

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Gavi</td>
<td>0.42%</td>
</tr>
<tr>
<td>Country</td>
<td>0.08%</td>
</tr>
<tr>
<td>GNI &lt; $1k</td>
<td></td>
</tr>
</tbody>
</table>

GNI < US $1,000 2,000
SHARING THE INVESTMENT

VACCINES AS % OF GENERAL GOVERNMENT SPENDING

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Gavi</strong></td>
<td>0.42%</td>
</tr>
<tr>
<td><strong>Country</strong></td>
<td>0.08%</td>
</tr>
<tr>
<td><strong>GNI &lt; $1k</strong></td>
<td></td>
</tr>
</tbody>
</table>

GNI = US $1,000-2,000

Gavi contribution 0.12%
Country contribution 0.03%
**VACCINES AS % OF GENERAL GOVERNMENT SPENDING**

<table>
<thead>
<tr>
<th></th>
<th>&lt; US $1k</th>
<th>$1-2k</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gavi</td>
<td>0.42%</td>
<td>0.12%</td>
</tr>
<tr>
<td>Country</td>
<td>0.08%</td>
<td>0.03%</td>
</tr>
</tbody>
</table>

**GNI > US $3,000 -2,000**
SHARING THE INVESTMENT

VACCINES AS % OF GENERAL GOVERNMENT SPENDING

<table>
<thead>
<tr>
<th></th>
<th>Gavi</th>
<th>Country</th>
<th>GNI</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>0.42%</td>
<td>0.08%</td>
<td>&lt; $1k</td>
</tr>
<tr>
<td></td>
<td>0.12%</td>
<td>0.03%</td>
<td>$1-2k</td>
</tr>
</tbody>
</table>

GNI > US $3,000
**SHARING THE INVESTMENT**

**VACCINES AS % OF GENERAL GOVERNMENT SPENDING**

<table>
<thead>
<tr>
<th></th>
<th>Gavi</th>
<th>Country</th>
<th>GNI</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>0.42%</td>
<td>0.08%</td>
<td>&lt; $1k</td>
</tr>
<tr>
<td></td>
<td>0.12%</td>
<td>0.03%</td>
<td>$1-2k</td>
</tr>
<tr>
<td></td>
<td>0.01%</td>
<td>0.01%</td>
<td>&gt; $3k</td>
</tr>
</tbody>
</table>

GNI > US $3,000  
Self-financing

Access to Gavi vaccine tenders for 5 years

Gavi contribution

Country contribution

Ongoing Affordability

Note: Vaccines for routine immunisation only. Cuba, Djibouti, India, DPR Korea, Somalia and Zimbabwe excluded from analysis.
Sources: World Bank GNI pc data as published 1 July 2015, IMF, WHO National Health Accounts/Gavi Adjusted Demand Forecast v12
THE COST OF INACTION

**SARS**
$50 billion
Estimated damage to the global economy 2003

**Ebola**
$2.2 billion
Estimated GDP losses for Guinea, Liberia & Sierra Leone in 2015

Sources:
SARS: The Economist, Aug 2014
EBOLA: WHO Pandemic Emergency Facility, FAQ, Jan 2016
GLOBAL HEALTH SECURITY

Detect
Prevent
Respond
GAVI SUPPORT BRINGS SUCCESS

- 500 million children immunised
- 7 million future deaths averted
- 300 vaccine introductions & campaigns
GRAND HEALTH CONVERGENCE

Under-5 mortality (deaths per 1,000 live births)

Countries with the lowest child mortality

Countries with the highest child mortality

CONVERGENCE TARGET

2063
TAKING ACTION

1. **Prioritise** investment in immunisation
2. Ensure vaccine line-item in **health budgets**
3. **Focus on equity** by investing in health to fully immunise every child
4. **Act now** to achieve the 2030 SDG's and be on track for Agenda 2063
5. Become an immunisation **champion**